Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mavyret (glecaprevir and pibrentasvir)
Special Reports
The top 10 drug launches since 2017
After years of R&D finally yield an approval, drugmakers hope for a continuous, abundant flow of revenue. And it all starts with a successful launch.
Angus Liu
May 18, 2020 3:00am
No love for Merck, BMS PD-1s on China's reimbursement list
Dec 2, 2019 11:59am
Gilead’s hep C generics now own more than 20% of market
Sep 16, 2019 11:34am
FDA flags liver risks for AbbVie, Merck, Gilead hep C meds
Aug 29, 2019 10:45am
Gilead airs first ads for hep C brand Epclusa
Feb 4, 2019 10:22am
AbbVie's latest hep C ads highlight Mavyret's time-to-cure edge
Dec 12, 2018 11:10am